Bacterial resistance in rectal flora before prostate biopsy in mexican population
DOI:
https://doi.org/10.48193/revistamexicanadeurologa.v81i4.789Keywords:
prostatic biopsy, bacterial resistance, fluoroquinolonesAbstract
Abstract
Background: The diagnosis of prostate cancer is accomplished with the use of prostatic biopsy. Although the transperineal access has emerged and been used more commonly, the transrectal approach is still the most performed globally. Infectious complications following biopsy are the most important and serious. The use of prophylactic antibiotics is a common practice. Fluoroquinolones have been the most used antibiotics worldwide and remain the first option before prostate biopsy. However, the resistance to these antibiotics has been rising dramatically in the last decades. Resistance shows different numbers in each country and region. The choice of antibiotic will depend on the local sensibilities reported.
Aim: To determine de prevalence of fluoroquinolone and othe antibiotic resistance in patients that come to our hospital for a prostate biopsy.
Material and methods: We performed a rectal swab in patients in whom a prostate biopsy was performed. Culture results were obtained and a descriptive analysis of resistance and sensibilities were obtained.
Results: We performed 126 rectal swabs. The main microorganism found in rectal cultures was E.coli. In our study we found a resistance to fluoroquinolones of 83%. The highest sensibility was for carbapenemics. None of our patients developed infectious complications.
Conclusion: We found a resistance rate in rectal flora before prostate biopsy of 83% to fluoroquinolones. We didn´t observe infectious complications in the patients included in our study. The use of antibiotics, bowel preparation, and negative urine culture diminish the possibilities of infectious complications. Although transperineal biopsy offers a minimal risk of infection, patients show more symptoms following this procedure. To our knowledge there are no reports of antibiotic resistance in rectal flora in our population.
References
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013 Dec;64(6):876–92. doi: https://doi.org/10.1016/j.eururo.2013.05.049
Trujillo CG, Plata M, Caicedo JI, Cataño Cataño JG, Mariño Alvarez AM, Castelblanco D, et al. Impact of Rectal Swabs on Infectious Complications after Transrectal Prostate Biopsy. Urol Int. 2016;97(3):340–6. doi: https://doi.org/10.1159/000448595
Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998 Oct;52(4):552–8. doi: https://doi.org/10.1016/s0090-4295(98)00296-9
Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000 Apr;85(6):682–5. doi: https://doi.org/10.1046/j.1464-410x.2000.00576.x
Sieber PR, Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Harpster LE. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997 Jun;157(6):2199–200. doi: https://doi.org/10.1016/S0022-5347(01)64716-5
Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial sepsis after prostate biopsy--a new perspective. Urology. 2009 Dec;74(6):1200–5. doi: https://doi.org/10.1016/j.urology.2009.07.1222
Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? J Urol. 2008 Mar;179(3):952–5; discussion 955. doi: https://doi.org/10.1016/j.juro.2007.10.071
Roberts MJ, Williamson DA, Hadway P, Doi SAR, Gardiner RA, Paterson DL. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. Int J Antimicrob Agents. 2014 Apr;43(4):301–9. doi: https://doi.org/10.1016/j.ijantimicag.2014.01.008
Wendel RG, Evans AT. Complications of punch biopsy of the prostate gland. J Urol. 1967 Jan;97(1):122–6. doi: https://doi.org/10.1016/s0022-5347(17)62995-1
Davison P, Malament M. Urinary contamination as a result of transrectal biopsy of the prostate. J Urol. 1971 Apr;105(4):545–6. doi: https://doi.org/10.1016/s0022-5347(17)61571-4
Fawcett DP, Eykyn S, Bultitude MI. Urinary tract infection following trans-rectal biopsy of the prostate. Br J Urol. 1975 Dec;47(6):679–81. doi: https://doi.org/10.1111/j.1464-410x.1975.tb04036.x
NCCN. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection Version 2.2020. National Comprehensive Cancer Network; 2020. 54 p.
Wolf JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008 Apr;179(4):1379–90. doi: https://doi.org/10.1016/j.juro.2008.01.068
Alidjanov JF, Cai T, Bartoletti R, Bonkat G, Bruyère F, Köves B, et al. The negative aftermath of prostate biopsy: prophylaxis, complications and antimicrobial stewardship: results of the global prevalence study of infections in urology 2010-2019. World J Urol. 2021 Feb 22; doi: https://doi.org/10.1007/s00345-021-03614-8
Siriboon S, Tiengrim S, Taweemongkongsup T, Thamlikitkul V, Chayakulkeeree M. Prevalence of antibiotic resistance in fecal flora of patients undergoing transrectal ultrasound-guided prostate biopsy in Thailand. Urol Int. 2012;88(2):187–93. doi: https://doi.org/10.1159/000335506
Van Besien J, Uvin P, Van den Abeele AM, Merckx L. Prevalence, Risk Factors, and Clinical Relevance of Fluoroquinolone-Resistant Organisms in Rectal Cultures: Should We Target Antibiotic Prophylaxis Prior to Prostate Biopsy? Adv Urol. 2016 Mar 1;2016:e5392107. doi: https://doi.org/10.1155/2016/5392107
Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, Petit PL, et al. Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. J Antimicrob Chemother. 2000 Aug;46(2):223–8. doi: https://doi.org/10.1093/jac/46.2.223
Minamida S, Satoh T, Tabata K, Kimura M, Tsumura H, Kurosaka S, et al. Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology. 2011 Dec;78(6):1235–9. doi: https://doi.org/10.1016/j.urology.2011.07.1392
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012 Jun;18(6):575–81. doi: https://doi.org/10.1111/j.1469-0691.2011.03638.x
Liss MA, Kim W, Moskowitz D, Szabo RJ. Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis. J Urol. 2015 Aug;194(2):397–402. doi: https://doi.org/10.1016/j.juro.2015.03.110
Pilatz A, Dimitropoulos K, Veeratterapillay R, Yuan Y, Omar MI, MacLennan S, et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2020 Aug;204(2):224–30. doi: https://doi.org/10.1097/ju.0000000000000814
